Loading...
Market
What will be Novavax's Nuvaxovid market share in the EU by end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from health market research firms
Story
Novavax's Shares Rise as EU Authorizes Updated Nuvaxovid COVID-19 Vaccine Targeting JN.1 Strain
Oct 9, 2024, 12:30 PM
Novavax Inc.'s updated 2024-2025 Nuvaxovid COVID-19 vaccine has received authorization from the European Commission, the company announced on Wednesday. The vaccine, which targets the JN.1 strain of the coronavirus, is approved for preventing COVID-19 in individuals aged 12 years and older across the European Union. Following the news, Novavax's shares rose 3.2% in premarket trading.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 30% • 25%
30% to 50% • 25%
50% to 70% • 25%
More than 70% • 25%
Yes • 50%
No • 50%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 5 million • 25%
5 million to 10 million • 25%
10 million to 15 million • 25%
More than 15 million • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%